Get all premium features to the best stock analysis tool

GoHealth (GOCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Dallas, Texas--(Newsfile Corp. - April 16, 2026) - GoHealth Inc. (NASDAQ: GOCO): Stonegate Capital Partners Updates Coverage on GoHealth Inc. (NASDAQ: GOCO). GoHealth's 4Q25 results continued to reflect a Medicare Advantage environment shaped by tighter carrier discipline, with management prioritizing retention, member quality, and liquidity over volume.

LOS ANGELES, April 13, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises GoHealth , Inc. , (“ GoHealth " or the "Company") ( NASDAQ : GOCO ) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.

GoHealth (GOCO) came out with a quarterly loss of $1.03 per share versus the Zacks Consensus Estimate of a loss of $2.69. This compares to earnings of $2.41 per share a year ago.

Dallas, Texas--(Newsfile Corp. - November 17, 2025) - GoHealth Inc. (NASDAQ: GOCO): Stonegate Capital Partners updates their coverage on GoHealth Inc. (NASDAQ: GOCO). GoHealth, Inc. reported a difficult 3Q25 as the Company continued to navigate a materially different Medicare Advantage environment.

GoHealth, Inc. ( GOCO ) Q3 2025 Earnings Call November 13, 2025 8:00 AM EST Company Participants John Shave - Vice President of Investor Relations Vijay Kotte - CEO & Director Conference Call Participants Robert McGuire - Granite Research, LLC Patrick McCann - NOBLE Capital Markets, Inc., Research Division Benjamin Hendrix - RBC Capital Markets, Research Division James Sidoti - Sidoti & Company, LLC David Storms - Stonegate Capital Partners, Inc., Research Division Presentation Operator Good day, and welcome to the GoHealth Third Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded.

GoHealth (GOCO) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $2.06. This compares to a loss of $3.73 per share a year ago.